Certara Reports First Quarter 2022 Financial Results

PRINCETON, N.J.—May 5, 2022– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2022. First Quarter Highlights: Revenue was $81.6 million, compared to $66.7 million in the first quarter of 2021, representing growth of 22% over the first quarter of 2021. Excluding Pinnacle … Continued

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J.— May 3, 2022 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Bank of America 2022 Healthcare ConferenceDate and Time: Tuesday, May 10 at 3:00 p.m. ET Citi’s Biopharma Virtual Co-Panel DayDate and Time: Wednesday, May 18 at 10:00 a.m. … Continued

Certara Reports Fourth Quarter and Full Year 2021 Financial Results

PRINCETON, N.J.—March 1, 2022– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021 and updated guidance for 2022. Fourth Quarter Highlights: Revenue was $75.3 million, compared to $64.6 million in the fourth quarter of 2020, representing growth of 17% over the … Continued

U.S. FDA Licenses Certara’s Immunogenicity Simulator

Affirms the advancements of innovative biosimulation technology and its growing impact in R&D PRINCETON, N.J.— February 23, 2022 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed Certara’s Immunogenicity (IG) Simulator to research and evaluate immunogenicity in protein-based therapeutics. Certara’s IG Simulator … Continued

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year

Asserts Certara’s leadership in advancing the development and approval of new drugs for patients PRINCETON, N.J.— February 15, 2022 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Review (CDER) were received … Continued

Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions

FDA holds more than 400 SimcypTM and PhoenixTM software licenses across 12 divisions and offices PRINCETON, N.J.— December 21, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and expanded its licenses of Certara’s proprietary biosimulation software, with more than 400 … Continued

Certara Announces Release of Pinnacle 21 Enterprise Software

New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients PRINCETON, N.J., Dec. 13, 2021 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release of Pinnacle 21 Enterprise 5.1.0, which updates the Company’s flagship software for preparing clinical trial data for biosimulation and regulatory submission. “With today’s … Continued

Certara to Host Investor Day on December 15, 2021

PRINCETON, N.J.— December 8, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City.  Certara’s management team will provide updates on the Company’s strategy, differentiated software and technology-driven services, and financial guidance for … Continued

1 of 29
Back to top
Powered by Translations.com GlobalLink OneLink Software